Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Argus Research Upgrades Biogen to Buy

Argus Research Upgrades Biogen to Buy

Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy.

byBenzinga Newsdesk

October 7, 2022

1 minute read

Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy.

Tryp Submits IND Application To FDA For Clinical Trial Of Psilocybin-Assisted Psychotherapy In Patients With IBS

By Vuk Zdinjak

May 24, 10:57 AM

Tryp Therapeutics, Inc. (OTCQB: TRYPF) (CSE:TRYP) has submitted an Investigational New Drug application to the U.S.

CSE:TRYP

News

Datadog Introduces Intelligent Test Runner To Help Developers Reduce The Time To Deploy Application Changes

By Happy Mohamed

August 3, 1:02 PM

By eliminating the need to test every code change, the new product helps development teams save time, minimize failures and optimize costs SAN FRANCISCO, Aug. 3, 2023 /PRNewswire/ -- Datadog, Inc.

DDOG

Riskified Analysts Boost Their Forecasts After Strong Q1 Results

By Avi Kapoor

May 16, 8:41 AM

Riskified Ltd. (NYSE:RSKD) reported better-than-expected first-quarter financial results on Wednesday. Riskified reported quarterly earnings of 4 cents per…

RSKD

Mizuho Maintains Buy on Universal Health Services, Lowers Price Target to $121

By Benzinga Newsdesk

July 1, 7:38 AM

Mizuho analyst Ann Hynes maintains Universal Health Services (NYSE:UHS) with a Buy and lowers the price target from $153 to $121.

UHS

Argus Research Upgrades Biogen to Buy

Related Posts

Tryp Submits IND Application To FDA For Clinical Trial Of Psilocybin-Assisted Psychotherapy In Patients With IBS

Datadog Introduces Intelligent Test Runner To Help Developers Reduce The Time To Deploy Application Changes

Riskified Analysts Boost Their Forecasts After Strong Q1 Results

Mizuho Maintains Buy on Universal Health Services, Lowers Price Target to $121